AURKB and lung carcinoma: Barasertib (AZD1152), an ATP-competitive inhibitor, has shown high selectivity for AurB and efficacy in preclinical models, inducing mitotic defects and apoptosis in acute myeloid leukemia (AML) and lung cancer [15,16].